JP2023516957A5 - - Google Patents

Info

Publication number
JP2023516957A5
JP2023516957A5 JP2022551653A JP2022551653A JP2023516957A5 JP 2023516957 A5 JP2023516957 A5 JP 2023516957A5 JP 2022551653 A JP2022551653 A JP 2022551653A JP 2022551653 A JP2022551653 A JP 2022551653A JP 2023516957 A5 JP2023516957 A5 JP 2023516957A5
Authority
JP
Japan
Prior art keywords
daptomycin
excipient
solid
reconstitution time
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/054841 external-priority patent/WO2021170807A1/en
Publication of JP2023516957A publication Critical patent/JP2023516957A/ja
Publication of JP2023516957A5 publication Critical patent/JP2023516957A5/ja
Priority to JP2025120933A priority Critical patent/JP2025142200A/ja
Pending legal-status Critical Current

Links

JP2022551653A 2020-02-28 2021-02-26 ダプトマイシン製剤 Pending JP2023516957A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120933A JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
US62/982,945 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120933A Division JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Publications (2)

Publication Number Publication Date
JP2023516957A JP2023516957A (ja) 2023-04-21
JP2023516957A5 true JP2023516957A5 (cg-RX-API-DMAC7.html) 2023-12-07

Family

ID=74797935

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551653A Pending JP2023516957A (ja) 2020-02-28 2021-02-26 ダプトマイシン製剤
JP2025120933A Pending JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120933A Pending JP2025142200A (ja) 2020-02-28 2025-07-18 ダプトマイシン製剤

Country Status (9)

Country Link
US (1) US12629337B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110303A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516957A (cg-RX-API-DMAC7.html)
CN (2) CN118873500A (cg-RX-API-DMAC7.html)
AU (1) AU2021227095B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022015571A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022010378A (cg-RX-API-DMAC7.html)
WO (1) WO2021170807A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208343B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
WO2026111848A1 (en) * 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2013103801A1 (en) 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
NO2887953T3 (cg-RX-API-DMAC7.html) 2012-08-23 2018-03-10
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2016098009A1 (en) 2014-12-16 2016-06-23 Dr. Reddy’S Laboratories Limited Lyophilized injectable compositions of daptomycin
CN106943587B (zh) 2016-01-06 2021-06-22 山东新时代药业有限公司 一种注射用达托霉素冻干粉针及其制备工艺
US11759497B2 (en) * 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation

Similar Documents

Publication Publication Date Title
JP4612923B2 (ja) 安定化された4−アミノ−3−置換−ブタン酸誘導体含有製剤およびその製造法
CN102202688B (zh) 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法
JP2021521159A5 (cg-RX-API-DMAC7.html)
JP2020530845A5 (cg-RX-API-DMAC7.html)
WO2012043696A1 (ja) 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのメグルミン塩
JP2020502183A5 (cg-RX-API-DMAC7.html)
CN110062620A (zh) 液体药物组合物
WO2020001203A1 (zh) 一种复方氨基酸维生素注射液及其应用
US20170189528A1 (en) Stable aqueous adalimumab formulation
JP2025142200A (ja) ダプトマイシン製剤
CN113811290A (zh) 达托霉素水性制剂
TWI791717B (zh) 冷凍乾燥製劑之製造方法
TW202017588A (zh) Hgf冷凍乾燥製劑
TW201538155A (zh) 活性成份輔助組成物及將活性成份化合物遞送給對象之方法
JPS61247354A (ja) 栄養素組成物
IL311344A (en) Preparations and methods for the treatment of synoclinopathies
JP2024520526A5 (cg-RX-API-DMAC7.html)
WO2018003946A1 (ja) 凍結乾燥製剤の製造方法
RU2016121401A (ru) Устойчивые при хранении лиофилизованные составы трипептидов
JP2025533238A (ja) 液体ダルババンシン組成物
CA3139341A1 (en) Stable albuvirtide compositions
RU2018113706A (ru) Стабильные высококонцентрированные водные композиции ранибизумаба с пролонгированным действием при интравитреальном введении для медицинского применения
JPWO2004028557A1 (ja) 安定化されたタンパク組成物
KR102692727B1 (ko) 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
WO2020055360A2 (en) The parenteral composition comprising carfilzomib